57 results on '"Kim, Min Kyoung"'
Search Results
2. Tumor-mediated 4-1BB induces tumor proliferation and metastasis in the colorectal cancer cells
3. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System
4. Predictive Factors of Successful Percutaneous Cervical Nucleoplasty for the Treatment of Pain with Cervical Herniated Disk
5. Inhibition of DNA Methylation in the COL1A2 Promoter by Anacardic Acid Prevents UV-Induced Decrease of Type I Procollagen Expression
6. Comparison of Laparoscopic Cornual Resection and Cornuotomy for Interstitial Pregnancy
7. Secretory factors of human chorion-derived stem cells enhance activation of human fibroblasts
8. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer
9. Identification and characterization of CW108F, a Novel β-carboline compound that promotes cardiomyogenesis of stem cells
10. Comparison of panic disorder with and without comorbid major depression by using brain structural magnetic resonance imaging
11. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
12. Biological Characterization of Nodal versus Extranodal Presentation of Diffuse Large B-Cell Lymphoma using Immunohistochemistry
13. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone
14. Initial Stage Affects Survival Even After Complete Pathologic Remission is Achieved in Locally Advanced Esophageal Cancer: Analysis of 70 Patients With Pathologic Major Response After Preoperative Chemoradiotherapy
15. Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome
16. Oral supplementation with NaFeEDTA reduces blood lead in postmenopausal but not premenopausal Korean women with anemia
17. P-106 Clinical outcomes of older patients aged 80 and over with newly diagnosed multiple myeloma
18. Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study
19. A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma
20. P-168: A multicenter prospective study for validation of the Korean Simple Geriatric Assessment Tool in elderly patients with multiple myeloma
21. P-142: Validation of new diagnostic criteria of primary plasma cell leukemia: a study of the Korean Multiple Myeloma Working Party (KMMWP-2003 study)
22. PLATELET-RICH PLASMA INCREASES HIF1a AND HIF2a IN ENDOMETRIUM AFFECTING LIVE BIRTH RATES IN MURINE ASHERMAN’S SYNDROME MODEL
23. Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era
24. Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)
25. Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)
26. Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y
27. Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma
28. the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study
29. Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
30. The outcomes of Korean Patients With Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)
31. 662: Placental transfer of dexamethasone in twin pregnancy compared to singleton pregnancy
32. The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)
33. A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia
34. Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma
35. Long-Term Follow-up of Continuous Imatinib Plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
36. Genetic Variations In Immune Regulatory Genes and The Risk For Diffuse Large B-Cell Lymphoma
37. Weekly Four Times Rituximab Consolidation Following Reduced Cycles Of R-CHOP Induction Chemotherapy In Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
38. Fludarabine, Cytarabine, and Attenuated-Dose Idarubicin (m-FLAI) Induction for Elderly Patients with Acute Myeloid Leukemia: Results of a Multicenter Phase II Study,
39. Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis
40. Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation
41. Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers
42. Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.
43. Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).
44. Clinical Features and Prognostic Relevance of Ovarian Involvement in Non-Hodgkin's Lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) Report.
45. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Incidence and Characteristics in Korean Patients.
46. The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotying in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.
47. Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).
48. Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84
49. Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?
50. Molecular Predictive Markers in Dose Escalation Treatment for Suboptimal Responders to Standard Dose Imatinib in CML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.